Angel Cobo, PhD
[PLACEHOLDER — opening line] I spend most of my working hours asking a question that sounds simple and almost never is: will this actually work in a person, not just on paper.
[PLACEHOLDER] I'm a scientist and drug development operator at Stanford's Innovative Medicines Accelerator, where I help move early-stage programs from an interesting result in a lab notebook toward something that can survive the much harder scrutiny of clinical development. Before this, I spent time on the other side of the table in venture, at Radicle Growth, evaluating biotech companies and the science underneath their pitch decks. That combination — building programs and diligencing them — shapes how I think more than either one alone would.
[PLACEHOLDER] What I care about isn't novelty for its own sake. It's translational risk: the gap between a compelling mechanism and a compound that actually changes outcomes for patients. Most of the interesting failures I've seen weren't failures of biology — they were failures of sequencing, of asking the expensive question too late, or the cheap question not at all. I try to work upstream of that.
[PLACEHOLDER] I'm drawn to teams and problems where scientific rigor and operational discipline have to coexist — where being right about the biology isn't enough if you can't also be right about timelines, capital, and what to do when the data disagrees with you.
Currently thinking about
[PLACEHOLDER] How translational risk gets systematically underweighted in early-stage decision-making, and what a better diligence framework for academic-to-industry drug programs might look like. More on this inWriting, eventually.
How I work
[PLACEHOLDER — short block on working style/values] Directly, with a bias toward the smallest experiment that would change my mind. I'd rather be corrected quickly than be comfortable for a long time.